Literature DB >> 26728996

Interdependence of DNA mismatch repair proteins MLH1 and MSH2 in apoptosis in human colorectal carcinoma cell lines.

Samar Hassen1, Akhtar A Ali1,2, Surya P Kilaparty1, Qudes A Al-Anbaky1, Waqar Majeed3, Bruce M Boman4,5,2, Jeremy Z Fields2, Nawab Ali6.   

Abstract

The mammalian DNA mismatch repair (MMR) system consists of a number of proteins that play important roles in repair of base pair mismatch mutations and in maintenance of genomic integrity. A defect in this system can cause genetic instability, which can lead to carcinogenesis. For instance, a germline mutation in one of the mismatch repair proteins, especially MLH1 or MSH2, is responsible for hereditary non-polyposis colorectal cancer. These MMR proteins also play an important role in the induction of apoptosis. Accordingly, altered expression of or a defect in MLH1 or MSH2 may confer resistance to anti-cancer drugs used in chemotherapy. We hypothesized that the ability of these two MMR proteins to regulate apoptosis are interdependent. Moreover, a defect in either one may confer resistance to chemotherapy by an inability to trigger apoptosis. To this end, we studied three cell lines-SW480, LoVo, and HTC116. These cell lines were selected based on their differential expression of MLH1 and MSH2 proteins. SW480 expresses both MLH1 and MSH2; LoVo expresses only MLH1 but not MSH2; HCT116 expresses only MSH2 but not MLH1 protein. MTT assays, a measure of cytotoxicity, showed that there were different cytotoxic effects of an anti-cancer drug, etoposide, on these cell lines, effects that were correlated with the MMR status of the cells. Cells that are deficient in MLH1 protein (HCT116 cells) were resistant to the drug. Cells that express both MLH1 and MSH2 proteins (SW480 cells) showed caspase-3 cleavage, an indicator of apoptosis. Cells that lack MLH1 (HCT116 cells) did not show any caspase-3 cleavage. Expression of full-length MLH1 protein was decreased in MMR proficient (SW480) cells during apoptosis; it remained unchanged in cells that lack MSH2 (LoVo cells). The expression of MSH2 protein remained unchanged during apoptosis both in MMR proficient (SW480) and deficient (HCT116) cells. Studies on translocation of MLH1 protein from nucleus to cytosolic fraction, an indicator of apoptosis, showed that MLH1 translocation only occurred in MMR proficient (SW480) cells upon induction of apoptosis further suggested a MSH2 dependent role of MLH1 in apoptosis. These data suggest a role of MLH1 in mediation of apoptosis in a MSH2-dependent manner. Taken together, our data supported an interdependence of mismatch repair proteins, particularly MLH1 and MSH2, in the mediation of apoptosis in human colorectal carcinoma cell lines.

Entities:  

Keywords:  Apoptosis; Colorectal cancer; Cytotoxicity; HNPCC; MLH1; MSH2; Mismatch repair proteins

Mesh:

Substances:

Year:  2016        PMID: 26728996     DOI: 10.1007/s11010-015-2636-3

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  23 in total

1.  Interaction of mismatch repair protein PMS2 and the p53-related transcription factor p73 in apoptosis response to cisplatin.

Authors:  Hideki Shimodaira; Atsuko Yoshioka-Yamashita; Richard D Kolodner; Jean Y J Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-24       Impact factor: 11.205

2.  Changes in cellular levels of inositol polyphosphates during apoptosis.

Authors:  Rakhee Agarwal; Samar Hassen; Nawab Ali
Journal:  Mol Cell Biochem       Date:  2010-08-20       Impact factor: 3.396

3.  Morphological and molecular evidence of differentiation during etoposide-induced apoptosis in human lymphoblastoid cells.

Authors:  C D Ramirez; R J Sleiman; D R Catchpoole; B W Stewart
Journal:  Cell Death Differ       Date:  2000-06       Impact factor: 15.828

Review 4.  Strand-specific mismatch repair in mammalian cells.

Authors:  P Modrich
Journal:  J Biol Chem       Date:  1997-10-03       Impact factor: 5.157

5.  The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells.

Authors:  S Jacob; M Aguado; D Fallik; F Praz
Journal:  Cancer Res       Date:  2001-09-01       Impact factor: 12.701

Review 6.  Dysregulation of apoptosis in cancer.

Authors:  J C Reed
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

7.  Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents.

Authors:  M J Hickman; L D Samson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-14       Impact factor: 11.205

Review 8.  DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis.

Authors:  Carol Bernstein; Harris Bernstein; Claire M Payne; Harinder Garewal
Journal:  Mutat Res       Date:  2002-06       Impact factor: 2.433

9.  Dependence of the cytotoxicity of DNA-damaging agents on the mismatch repair status of human cells.

Authors:  Efterpi Papouli; Petr Cejka; Josef Jiricny
Journal:  Cancer Res       Date:  2004-05-15       Impact factor: 12.701

10.  Human MLH1 protein participates in genomic damage checkpoint signaling in response to DNA interstrand crosslinks, while MSH2 functions in DNA repair.

Authors:  Qi Wu; Karen M Vasquez
Journal:  PLoS Genet       Date:  2008-09-12       Impact factor: 5.917

View more
  7 in total

1.  Role of inositol polyphosphates in programed cell death in Dictyostelium discoideum and its developmental life cycle.

Authors:  Qudes Al-Anbaky; Zeiyad Al-Karakooly; Richard Connor; Lisa Williams; Azure Yarbrough; John Bush; Nawab Ali
Journal:  Mol Cell Biochem       Date:  2018-04-20       Impact factor: 3.396

2.  Mismatch repair deficiency, chemotherapy and survival for resectable gastric cancer: an observational study from the German staR cohort and a meta-analysis.

Authors:  J Schumacher; P Malfertheiner; M Venerito; T Stolze; S Franke; J Haybaeck; M Moehler; P P Grimminger; H Lang; W Roth; I Gockel; N Kreuser; H Bläker; C Wittekind; F Lordick; M Vieth; L Veits; O Waidmann; P Lingohr; U Peitz; C Schildberg; M Kruschewski; N Vassos; E Goni; C J Bruns; K Ridwelski; S Wolff; H Lippert
Journal:  J Cancer Res Clin Oncol       Date:  2022-02-25       Impact factor: 4.553

Review 3.  Unboxing the molecular modalities of mutagens in cancer.

Authors:  Smita Kumari; Sudhanshu Sharma; Dia Advani; Akanksha Khosla; Pravir Kumar; Rashmi K Ambasta
Journal:  Environ Sci Pollut Res Int       Date:  2021-10-05       Impact factor: 5.190

4.  Mismatch Repair Proteins in Oropharyngeal Squamous Cell Carcinoma: A Retrospective Observational Study.

Authors:  Osias Vieira de Oliveira Filho; Thinali Sousa Dantas; Isabelle Joyce de Lima Silva-Fernandes; Maria do Perpétuo Socorro Saldanha Cunha; Ana Paula Negreiros Nunes Alves; Mário Rogério Lima Mota; Paulo Goberlânio de Barros Silva; Fabrício Bitu Sousa
Journal:  Head Neck Pathol       Date:  2021-01-27

5.  5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers.

Authors:  Lauren Van Der Kraak; Gaurav Goel; Rajeev Dhupar; Michael T Lotze; Krishnaveni Ramanan; Christof Kaltenmeier; Lin Zhang; Daniel P Normolle; Gordon J Freeman; Daolin Tang; Katie S Nason; Jon M Davison; James D Luketich
Journal:  J Immunother Cancer       Date:  2016-10-18       Impact factor: 13.751

6.  Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells.

Authors:  Natalia Motta Leguisamo; Jenifer Saffi; Helena de Castro E Gloria; Laura Jesuíno Nogueira; Patrícia Bencke Grudzinski; Paola Victória da Costa Ghignatti; Temenouga Nikolova Guecheva
Journal:  BMC Cancer       Date:  2021-04-22       Impact factor: 4.430

7.  C. tropicalis promotes chemotherapy resistance in colon cancer through increasing lactate production to regulate the mismatch repair system.

Authors:  Junxing Qu; Zhiheng Sun; Chen Peng; Daoqian Li; Wenyue Yan; Zhen Xu; Yayi Hou; Sunan Shen; Ping Chen; Tingting Wang
Journal:  Int J Biol Sci       Date:  2021-07-02       Impact factor: 6.580

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.